Bart Van Wijmeersch

4.6k total citations
78 papers, 2.0k citations indexed

About

Bart Van Wijmeersch is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Bart Van Wijmeersch has authored 78 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pathology and Forensic Medicine, 20 papers in Immunology and 14 papers in Neurology. Recurrent topics in Bart Van Wijmeersch's work include Multiple Sclerosis Research Studies (56 papers), T-cell and B-cell Immunology (13 papers) and Peripheral Neuropathies and Disorders (11 papers). Bart Van Wijmeersch is often cited by papers focused on Multiple Sclerosis Research Studies (56 papers), T-cell and B-cell Immunology (13 papers) and Peripheral Neuropathies and Disorders (11 papers). Bart Van Wijmeersch collaborates with scholars based in Belgium, United States and Germany. Bart Van Wijmeersch's co-authors include Piet Stinissen, Veerle Somers, Niels Hellings, Peter Feys, Bieke Broux, Marjan Vanheusden, Judith Fraussen, Raymond Hupperts, Nele Claes and Ilse Lamers and has published in prestigious journals such as Journal of Neuroscience, The Journal of Immunology and PLoS ONE.

In The Last Decade

Bart Van Wijmeersch

70 papers receiving 2.0k citations

Peers

Countries citing papers authored by Bart Van Wijmeersch

Since Specialization

Citations

This map shows the geographic impact of Bart Van Wijmeersch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Van Wijmeersch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Van Wijmeersch more than expected).

Fields of papers citing papers by Bart Van Wijmeersch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Van Wijmeersch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Van Wijmeersch. The network helps show where Bart Van Wijmeersch may publish in the future.

Co-authorship network of co-authors of Bart Van Wijmeersch

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Van Wijmeersch. A scholar is included among the top collaborators of Bart Van Wijmeersch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Van Wijmeersch. Bart Van Wijmeersch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rapamycin rescues loss of function in blood-brain barrier–interacting Tregs 2024 ·JCI Insight ·(unknown), Ibrahim Hamad, (unknown), Michael Hiltensperger, Bart Van Wijmeersch, Veronica Popescu, Lilian Aly, Veerle Somers, Thomas Korn, Markus Kleinewietfeld, Niels Hellings, Bieke Broux	4
2	Multiple Sclerosis Multidisciplinary Care: A National Survey and Lessons for the Global Community 2024 ·Multiple Sclerosis and Related Disorders ·Liesbeth Van Hijfte, Melissa Cambron, (unknown), Bernard Dachy, D. Decoo, Dominique Dive, Bénédicte Dubois, Souraya El Sankari, Frédéric London, Gaetano Perrotta, Veronica Popescu, Vincent Van Pesch, Bart Van Wijmeersch, Barbara Willekens, Guy Laureys	1
3	Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort 2023 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), Deborah Severijns, Veronica Popescu, Liesbet M. Peeters, Bart Van Wijmeersch	7
4	Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis 2020 ·BMC Neurology ·J. Yperman, (unknown), Dirk Valkenborg, Veronica Popescu, Niels Hellings, Bart Van Wijmeersch, Liesbet M. Peeters	47
5	Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study 2020 ·CNS Drugs ·Tjalf Ziemssen, Ann Bass, Regina Berkovich, Giancarlo Comi, (unknown), Jeremy Hobart, Samuel F. Hunter, Christopher LaGanke, Volker Limmroth, Daniel Pelletier, Carlo Pozzilli, Sven Schippling, Lívia Sousa, Anthony Traboulsee, Bernard M.J. Uitdehaag, Bart Van Wijmeersch, Zia Choudhry, Nadia Daizadeh, B. Singer, (unknown)	43
6	Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgD−CD27− Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients 2019 ·The Journal of Immunology ·Judith Fraussen, Susanna Marquez, Kazushiro Takata, (unknown), (unknown), Chrysoula Zografou, Bart Van Wijmeersch, Luisa María Villar, Kevin C. O’Connor, Steven H. Kleinstein, Veerle Somers	36
7	Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies 2019 ·Multiple Sclerosis Journal ·Bart Van Wijmeersch, B. Singer, Aaron Boster, Simon Broadley, Óscar Fernández, Mark S. Freedman, Guillermo Izquierdo, Jan Lycke, Carlo Pozzilli, Basil Sharrack, Brian Steingo, Heinz Wiendl, Sibyl Wray, Tjalf Ziemssen, (unknown), David Margolin, Karthinathan Thangavelu, Patrick Vermersch	16
8	Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management 2018 ·Acta Neurologica Belgica ·Brigitte Decallonne, E Bartholomé, Valérie Delvaux, Miguel D’haeseleer, Souraya El Sankari, Pierrette Seeldrayers, Bart Van Wijmeersch, Chantal Daumerie	28
9	Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study 2018 ·Multiple Sclerosis and Related Disorders ·Marie D’hooghe, Geert Van Gassen, Daphne Kos, (unknown), Melissa Cambron, D. Decoo, Andreas Lysandropoulos, Bart Van Wijmeersch, Barbara Willekens, Iris‐Katharina Penner, Guy Nagels	43
10	Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study (S10.002) 2017 ·Neurology ·Douglas L. Arnold, Michael Barnett, Cristoforo Comi, Gavin Giovannoni, Daniel Pelletier, Àlex Rovira, Sven Schippling, Bart Van Wijmeersch, David Margolin, Karthinathan Thangavelu, Anthony Traboulsee	0
11	Impact of Multiple Sclerosis on Patients’ Daily Activities, Emotional Well-Being and Relationships: Results of the Global vsMS™ Survey (P3.334) 2017 ·Neurology ·Ann Bass, Bart Van Wijmeersch, (unknown), Mathias Mäurer, (unknown), (unknown), B. Singer	2
12	Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression 2017 ·Frontiers in Immunology ·Liesbet M. Peeters, Marjan Vanheusden, Veerle Somers, Bart Van Wijmeersch, Piet Stinissen, Bieke Broux, Niels Hellings	58
13	Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation 2017 ·Scientific Reports ·Marjan Vanheusden, Bieke Broux, Suzanne P. M. Welten, Liesbet M. Peeters, Eleni Panagioti, Bart Van Wijmeersch, Veerle Somers, Piet Stinissen, Ramon Arens, Niels Hellings	49
14	Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study 2017 ·Multiple Sclerosis and Related Disorders ·Lars Costers, (unknown), (unknown), Jeroen Van Schependom, (unknown), Ann Van Remoortel, (unknown), Bart Van Wijmeersch, Pierrette Seeldrayers, Marie-Claire Haelewyck, Miguel D’haeseleer, Marie D’hooghe, Dawn Langdon, Guy Nagels	34
15	B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses 2016 ·Clinical Immunology ·Judith Fraussen, Nele Claes, Bart Van Wijmeersch, Jack van Horssen, Piet Stinissen, Raymond Hupperts, Veerle Somers	43
16	Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis 2014 ·Brain Behavior and Immunity ·Kris Janssens, Chris Van den Haute, Veerle Baekelandt, Sophie Lucas, Jack van Horssen, Veerle Somers, Bart Van Wijmeersch, Piet Stinissen, Jerome J. A. Hendriks, Helena Slaets, Niels Hellings	49
17	CX3CR1 drives cytotoxic CD4+CD28− T cells into the brain of multiple sclerosis patients 2011 ·Journal of Autoimmunity ·Bieke Broux, (unknown), Xin Zhang, Silva Markovic‐Plese, Tom Broekmans, Bert O. Eijnde, Bart Van Wijmeersch, Veerle Somers, Piet Geusens, Susanne van der Pol, Jack van Horssen, Piet Stinissen, Niels Hellings	104
18	Ablation of Proliferating Microglia Does Not Affect Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis Caused by Mutant Superoxide Dismutase 2008 ·Journal of Neuroscience ·Genevíève Gowing, Thomas Philips, Bart Van Wijmeersch, Jean‐Nicolas Audet, Maarten Dewil, Ludo Van Den Bosch, An Billiau, Wim Robberecht, Jean-Pierre Julien	114
19	Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: Perspective on mechanisms of action 2008 ·Journal of Neuroimmunology ·Bart Van Wijmeersch, Ben Sprangers, Bénédicte Dubois, Mark Waer, An Billiau	17
20	Experimental and clinical approaches for optimization of the graft-versus-leukemia effect 2007 ·Nature Clinical Practice Oncology ·Ben Sprangers, Bart Van Wijmeersch, Sabine Fevery, Mark Waer, An Billiau	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact